Skip to main content
Premium Trial:

Request an Annual Quote

Novartis and Compugen Launch RNA Interference Project

NEW YORK, Sept. 4-Novartis and Compugen are extending their research collaboration to include target validation and RNA interference research, the two companies said today.

 

The two companies intend to build a large-scale platform that can generate a library of transcript-inhibiting molecules. Compugen will own the platform and have rights to use it internally and as a commercial product. Novartis will use the system for its own research and will own the results of that work.

 

Novartis plans to use the RNAi platform to synthesize transcript-inhibiting molecules and use them to validate targets and evaluate gene function.

 

Last August, Compugen struck a major platform licensing and DNA chip design deal with Novartis as part of the pharmaceutical giant's efforts to establish a comprehensive human transcriptome database.

 

For further information, see the press release.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.